Journal of Solid Tumors最新文献

英文中文

Durable response in a thymic neuroendocrine tumor: A case report and review of the literature 胸腺神经内分泌肿瘤的持久反应:1例报告及文献回顾

Journal of Solid Tumors

Pub Date : 2017-04-19 DOI: 10.5430/JST.V7N2P23

Y. Syed, Daniel H Miller, Liuyan Jiang, Arya N. Bagherpour, S. Ko

Thymic neuroendocrine tumors are rare, representing less than 5% of all thymic cancers, and are biologically distinct in histology and behavior. Conclusive treatment guidelines are limited due to a lack of randomized clinical trials. Current literature, consisting mainly of case reports and series, suggests that complete surgical resection combined with adjuvant radiation therapy offers the greatest survival benefit for patients with thymic neuroendocrine tumors (NET). Adjuvant chemotherapy may also delay the onset of distant metastasis. Prognosis is generally poor, particularly in high-grade tumors, as these patients are prone to early metastasis. Here we present the case of a 62-year-old woman who achieved a durable response after undergoing an aggressive multimodal treatment approach for a primary thymic NET that initially presented as chronic cough and mild dyspnea on exertion.

胸腺神经内分泌肿瘤是罕见的，占所有胸腺肿瘤的不到5%，并且在组织学和行为上具有生物学上的独特性。由于缺乏随机临床试验，结论性治疗指南有限。目前主要由病例报告和系列文献组成的文献表明，胸腺神经内分泌肿瘤(NET)患者完全手术切除联合辅助放射治疗可获得最大的生存效益。辅助化疗也可能延缓远处转移的发生。预后通常较差，特别是高级别肿瘤，因为这些患者容易早期转移。在这里，我们报告了一名62岁的女性，她在接受积极的多模式治疗方法后获得了持久的反应，最初表现为慢性咳嗽和轻度呼吸困难。

引用次数: 0

Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests Braf p.V600E突变的检测是否可以提高?等位基因特异性多重序列与现有测试的比较

Journal of Solid Tumors

Pub Date : 2017-04-12 DOI: 10.5430/JST.V7N2P14

T. Vinayagamoorthy, David Y. Zhang, F. Ye, Dilanthi Vinayagamoorthy, R. Hodkinson

Objective: This is an investigative study to evaluate a new companion diagnostic platform, allele specific multiplex sequencing (ASMS). Detection of Braf p.V600E from solid tumors is used as the test model with the following objectives: 1) whether ASMS can detect Braf p.V600E/K mutations from a variety of solid tumors, 2) whether ASMS can detect all Braf p.V600E from samples that were positive for Braf V600E by SNaPshot or Ion Torrent, and 3) whether ASMS can detect Braf p.V600E among samples that were reported negative by SNaPshot or Ion Torrent. Methods: ASMS is a novel modification (US Patent 6197510) of traditional Sanger sequencing, with Lower Limit of Detection (LLOD) of 20 GE (Genome Equivalent) and 0.001% sensitivity. We compared ASMS to clinical samples previously tested either by SNaPshot or Ion Torrent methods. Results: We analyzed 83 DNA extracts from FFPE samples (41 tested by SNaPshot and 42 tested by Ion Torrent). There was a total of thirty-seven samples positive for Braf p.V600E (16 by Ion Torrent; 21 by SNaPshot), and all of these samples tested positive by ASMS for Braf p.V600E. Out of the 46 negatives for Braf p.V600E (20 by SNaPshot; 26 by Ion Torrent samples), ASMS detected Braf p.V600E positive results in 10 of the SNaPshot and in 18 of the Ion Torrent negative samples. ASMS could detect both Braf p.V600E and the wild-type Braf p.V600 simultaneously with 40 pg of FFPE DNA extracts. Conclusions: ASMS assay detected all Braf p.V600E positives from different types of solid tumors that previously tested positive by SNaPshot or Ion Torrent. Further, ASMS was able to detect Braf p.V600E among samples that were reported negative by SNaPshot or Ion Torrent.

目的:本研究旨在评价一种新的伴随诊断平台——等位基因特异性多重测序(ASMS)。检测实体肿瘤Braf p.V600E作为检验模型，目的如下:1)asm能否检测出多种实体肿瘤Braf p.V600E/K突变;2)在SNaPshot或Ion Torrent检测Braf p.V600E阳性的样本中，asm能否检测出所有Braf p.V600E; 3)在SNaPshot或Ion Torrent检测阴性的样本中，asm能否检测出Braf p.V600E。方法:ASMS是传统Sanger测序的新改良(美国专利6197510)，检测下限(LLOD)为20ge (Genome Equivalent)，灵敏度为0.001%。我们将ASMS与先前使用SNaPshot或Ion Torrent方法测试的临床样本进行比较。结果:我们分析了83份FFPE样品的DNA提取物(41份采用SNaPshot检测，42份采用Ion Torrent检测)。共有37份样本Braf p.V600E呈阳性(16份为离子激流检测;这些样本均经asm检测为Braf p.V600E阳性。在Braf p.V600E的46张底片中(20张由SNaPshot拍摄;26个离子激流样品)，asm在10个SNaPshot样品中检测到Braf p.V600E阳性结果，在18个离子激流样品中检测到阴性结果。用40 pg的FFPE DNA提取物同时检测Braf p.V600E和野生型Braf p.V600。结论:在不同类型的实体瘤中，asm检测到所有Braf p.V600E阳性，而之前的SNaPshot或Ion Torrent检测结果均为阳性。此外，asm能够在SNaPshot或Ion Torrent报告为阴性的样品中检测到Braf p.V600E。

{"title":"Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests","authors":"T. Vinayagamoorthy, David Y. Zhang, F. Ye, Dilanthi Vinayagamoorthy, R. Hodkinson","doi":"10.5430/JST.V7N2P14","DOIUrl":"https://doi.org/10.5430/JST.V7N2P14","url":null,"abstract":"Objective: This is an investigative study to evaluate a new companion diagnostic platform, allele specific multiplex sequencing (ASMS). Detection of Braf p.V600E from solid tumors is used as the test model with the following objectives: 1) whether ASMS can detect Braf p.V600E/K mutations from a variety of solid tumors, 2) whether ASMS can detect all Braf p.V600E from samples that were positive for Braf V600E by SNaPshot or Ion Torrent, and 3) whether ASMS can detect Braf p.V600E among samples that were reported negative by SNaPshot or Ion Torrent. Methods: ASMS is a novel modification (US Patent 6197510) of traditional Sanger sequencing, with Lower Limit of Detection (LLOD) of 20 GE (Genome Equivalent) and 0.001% sensitivity. We compared ASMS to clinical samples previously tested either by SNaPshot or Ion Torrent methods. Results: We analyzed 83 DNA extracts from FFPE samples (41 tested by SNaPshot and 42 tested by Ion Torrent). There was a total of thirty-seven samples positive for Braf p.V600E (16 by Ion Torrent; 21 by SNaPshot), and all of these samples tested positive by ASMS for Braf p.V600E. Out of the 46 negatives for Braf p.V600E (20 by SNaPshot; 26 by Ion Torrent samples), ASMS detected Braf p.V600E positive results in 10 of the SNaPshot and in 18 of the Ion Torrent negative samples. ASMS could detect both Braf p.V600E and the wild-type Braf p.V600 simultaneously with 40 pg of FFPE DNA extracts. Conclusions: ASMS assay detected all Braf p.V600E positives from different types of solid tumors that previously tested positive by SNaPshot or Ion Torrent. Further, ASMS was able to detect Braf p.V600E among samples that were reported negative by SNaPshot or Ion Torrent.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"74 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2017-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72678099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Unusual behaviour of a retroperitoneal sarcoma: A case report and review of the literature 腹膜后肉瘤的异常行为:一例报告和文献复习

Journal of Solid Tumors

Pub Date : 2017-01-18 DOI: 10.5430/JST.V7N1P57

A. Azzam, A. Elkak

Retroperitoneal sarcomas are aggressive tumours with a poor prognosis. Staging and prognostic criteria do not always predict the behaviour of these tumours. We report a case of retroperitoneal sarcoma which did not quite follow the known prognostic criteria.

腹膜后肉瘤是侵袭性肿瘤，预后较差。分期和预后标准并不总能预测这些肿瘤的行为。我们报告一例腹膜后肉瘤，不完全符合已知的预后标准。

引用次数: 0

Intravascular disseminated coagulopathy as a debut of metastatic prostate cancer: A case report 血管内弥散性凝血功能障碍是转移性前列腺癌的首次表现:1例报告

Journal of Solid Tumors

Pub Date : 2017-01-17 DOI: 10.5430/JST.V7N1P52

P. E. Olarte, Nerea Inés Muñoz Unceta, R. M. Kopp, J. Olmedo, D. C. Gauna, L. Paz-Ares

Hormonal therapy has been the treatment axis of metastatic prostate cancer since 1940. Identifying rare forms of debut is important in order to initiate the best treatment as soon as possible. Intravascular disseminated coagulopathy (DIC) related to prostate cancer is mostly presented as chronic forms. Acute forms can also be the way of presentation, recognizing them is crucial due to its life threatening nature. Here, we present a case of debut of metastatic prostate cancer as an acute DIC. Reporting this case is important because of the unfrequently presentation and to consider combined chemohormonal therapy since the diagnosis.

自1940年以来，激素治疗一直是转移性前列腺癌的治疗主轴。为了尽快开始最好的治疗，识别罕见的首发形式是很重要的。与前列腺癌相关的血管内弥散性凝血病(DIC)主要表现为慢性形式。急性形式也可以是一种表现方式，由于其威胁生命的性质，识别它们至关重要。在这里，我们提出一个病例转移性前列腺癌首次作为急性DIC。报告这个病例很重要，因为它很少出现，并且自诊断以来考虑联合化疗。

引用次数: 0

Correlation between Campanacci’s radiological classification of giant cell tumor of bone and expression of Cyclin D1 and PCNA 骨巨细胞瘤Campanacci放射学分型与Cyclin D1和PCNA表达的关系

Journal of Solid Tumors

Pub Date : 2017-01-10 DOI: 10.5430/JST.V7N1P47

E. Estrada-Villaseñor, Hidalgo Bravo Alberto, C. Bandala, P. D. L. Garza-Montano, Reyes Medina Naxieli, Pichardo Bahena Raúl, E. Delgado-Cedillo, L. Linares-González, G. Rico-Martínez

Giant cell tumor of bone is considered by his behavior a benign but aggressive neoplasm. The objective of our study was to determine if there is a correlation between the Campanacci’s radiological classification of giant cell tumors of bone and the expression by immunohistochemistry of Cyclin D1 and proliferation cell nuclear antibody (PCNA). A retrospective and descriptive study was made. In total, there were 27 cases. All cases showed Cyclin D1 and PCNA positivity. Rho Spearman for Campanacci and Cyclin D1 expression was 0.06 and for Campanacci and PCNA was 0.418. We conclude that there is a positive correlation between PCNA expression in giant cell tumors of Bone and the Campanacci’s radiological classification II and III, but Cyclin D1 expression was no related with radiologic features.

骨巨细胞瘤的行为被认为是一种良性但侵袭性的肿瘤。我们的研究目的是确定骨巨细胞瘤的Campanacci放射学分类与Cyclin D1和增殖细胞核抗体(增殖细胞核抗体，PCNA)的免疫组化表达是否存在相关性。进行回顾性和描述性研究。总共有27例。所有病例均显示Cyclin D1和PCNA阳性。Campanacci和Cyclin D1表达的Rho Spearman为0.06,Campanacci和PCNA表达的Rho Spearman为0.418。我们认为骨巨细胞瘤中PCNA的表达与Campanacci放射学ⅱ和ⅲ级呈正相关，而Cyclin D1的表达与放射学特征无关。

引用次数: 2

Prophylactic anticoagulant therapy decreases the incidence of deep vein thrombosis in patients with solid tumors: A systematic review and meta-analysis 预防性抗凝治疗降低实体肿瘤患者深静脉血栓的发生率:一项系统回顾和荟萃分析

Journal of Solid Tumors

Pub Date : 2017-01-03 DOI: 10.5430/JST.V7N1P35

Yunjiao Zhou, Gong Yang, Chenglei Huang

It is not well understood the efficacy and safety of primary deep vein thrombosis (DVT) prophylaxis of anticoagulants in patients with solid tumors. This systematic review and meta-analysis of randomized controlled trials (RCT) determines the relative ratio of primary DVT, survival rate and bleeding events among patients with solid tumors treated with anticoagulants or placebo. Comprehensive literature searches were conducted through the Pubmed, Ovid MEDLINE and EMBASE databases published from January 1st, 1993 to December 31st, 2015. Statistical analysis was performed by RevMan 5.0 software. For DVT events, the risk ratio in 16 trials between the prophylactic and control patients was statistically significant at 0.45 [0.36-0.58]; for major bleeding events, the risk ratio in 18 trials between the prophylactic and control patients was not statistically significant at 1.33 [0.99-1.79], while that in 15 trials with clinically relevant non-major bleeding was statistically significant at 1.83 [1.46-2.30]; the risk ratio for the mortality rate of patients with solid tumors in 16 trials was not statistically significant at 0.97 [0.93-1.02]. In conclusion, the risk ratio in this meta-analysis showed a significantly reduced incidence of DVT with anticoagulant use. Treatment to patients who had solid tumors with prophylactic anticoagulants enhanced the incidence rate of non-major bleeding but has no significant impact on the incidence rate of major bleeding. No significant differences were found in the mortality outcomes between anticoagulant and non-anticoagulant groups.

抗凝药物预防实体瘤患者原发性深静脉血栓形成(DVT)的疗效和安全性尚不清楚。本研究对随机对照试验(RCT)进行了系统回顾和荟萃分析，确定了接受抗凝剂或安慰剂治疗的实体肿瘤患者中原发性深静脉血栓形成的相对比例、生存率和出血事件。通过1993年1月1日至2015年12月31日出版的Pubmed、Ovid MEDLINE和EMBASE数据库进行综合文献检索。采用RevMan 5.0软件进行统计分析。在16项试验中，预防组与对照组DVT事件的风险比为0.45[0.36-0.58]，差异有统计学意义;对于大出血事件，18项试验中预防组与对照组的风险比为1.33[0.99-1.79]，无统计学意义;15项试验中与临床相关的非大出血事件的风险比为1.83[1.46-2.30]，有统计学意义;16项试验中实体瘤患者死亡率的风险比为0.97[0.93-1.02]，差异无统计学意义。综上所述，本荟萃分析的风险比显示抗凝剂的使用显著降低了DVT的发生率。对实体瘤患者进行预防性抗凝治疗可提高非大出血发生率，但对大出血发生率无显著影响。抗凝治疗组和非抗凝治疗组的死亡率无显著差异。

{"title":"Prophylactic anticoagulant therapy decreases the incidence of deep vein thrombosis in patients with solid tumors: A systematic review and meta-analysis","authors":"Yunjiao Zhou, Gong Yang, Chenglei Huang","doi":"10.5430/JST.V7N1P35","DOIUrl":"https://doi.org/10.5430/JST.V7N1P35","url":null,"abstract":"It is not well understood the efficacy and safety of primary deep vein thrombosis (DVT) prophylaxis of anticoagulants in patients with solid tumors. This systematic review and meta-analysis of randomized controlled trials (RCT) determines the relative ratio of primary DVT, survival rate and bleeding events among patients with solid tumors treated with anticoagulants or placebo. Comprehensive literature searches were conducted through the Pubmed, Ovid MEDLINE and EMBASE databases published from January 1st, 1993 to December 31st, 2015. Statistical analysis was performed by RevMan 5.0 software. For DVT events, the risk ratio in 16 trials between the prophylactic and control patients was statistically significant at 0.45 [0.36-0.58]; for major bleeding events, the risk ratio in 18 trials between the prophylactic and control patients was not statistically significant at 1.33 [0.99-1.79], while that in 15 trials with clinically relevant non-major bleeding was statistically significant at 1.83 [1.46-2.30]; the risk ratio for the mortality rate of patients with solid tumors in 16 trials was not statistically significant at 0.97 [0.93-1.02]. In conclusion, the risk ratio in this meta-analysis showed a significantly reduced incidence of DVT with anticoagulant use. Treatment to patients who had solid tumors with prophylactic anticoagulants enhanced the incidence rate of non-major bleeding but has no significant impact on the incidence rate of major bleeding. No significant differences were found in the mortality outcomes between anticoagulant and non-anticoagulant groups.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"6 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2017-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82825365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

¹⁸F-PET/CT imaging of metastasis to the thyroid gland: Imaging findings and effect on patient management. 甲状腺转移的18F-PET/CT成像:影像学表现及其对患者治疗的影响。

Journal of Solid Tumors

Pub Date : 2017-01-01 DOI: 10.5430/jst.v7n2p7

Giovanni G Millare, Michael Kwon, Beth S Edeiken-Monroe, J Matthew Debnam

Purpose: While metastasis to the thyroid from a primary cancer remote to the thyroid is uncommon, current imaging techniques have improved detection of these intrathyroid metastases. The purpose of this study was to evaluate the ¹⁸F-PET/CT appearance of intrathyroid metastases and assess the impact of detection on patient management.

Methods: The ¹⁸F-PET/CT appearance of intrathyroid metastasis, including standardized uptake value (SUV), disease extent, and the effect on patient management following diagnosis were retrospectively reviewed. Inclusion criteria included ¹⁸F-PET/CT imaging and diagnosis of the intrathyroid metastasis matching the remote primary tumor.

Results: Intrathyroid metastasis were detected in 24 patients. The intrathyroid metastases presented on ¹⁸F-PET/CT as focal nodular uptake (n = 21), multiple nodular uptake (n = 2), or diffuse uptake/infiltration of the thyroid gland (n = 1). The SUV ranged between 3.9 and 42 (median 12.5 ± 7.5); in 2 patients, the FDG-avidity was minimal. On ¹⁸F-PET/CT, distant metastases were present outside the neck (n = 18), or limited to the neck (n = 6). In 2 of these 6 patients, the thyroid was the only site of metastatic disease. Due to the metastatic disease, the therapy was changed in 23 of 24 patients; 1 patient was lost to follow-up.

Conclusion: In any patient with a previous or current history of an extrathyroid malignancy, an ¹⁸FDG-avid thyroid mass or diffuse infiltration of the thyroid on ¹⁸F-PET/CT should be considered a potential intrathyoid metastasis until proven otherwise. Knowledge of an intrathyroid metastasis may impact patient management, especially if the thyroid or neck are the only sites of metastatic disease.

目的:虽然原发癌远端转移到甲状腺的情况并不常见，但目前的影像学技术已经提高了对甲状腺内转移的检测。本研究的目的是评估甲状腺内转移的18F-PET/CT表现，并评估检测对患者治疗的影响。方法:回顾性分析甲状腺内转移的18F-PET/CT表现，包括标准化摄取值(SUV)、病变程度及对患者治疗的影响。纳入标准包括18F-PET/CT影像和诊断甲状腺内转移与远处原发肿瘤相匹配。结果:24例患者有甲状腺内转移。18F-PET/CT表现为局灶性结节性摄取(n = 21)、多发结节性摄取(n = 2)或甲状腺弥漫性摄取/浸润(n = 1)。SUV范围在3.9 ~ 42(中位数12.5±7.5);2例患者fdg贪婪度极低。在18F-PET/CT上，远处转移灶出现在颈部外(n = 18)，或局限于颈部(n = 6)。在这6例患者中，2例甲状腺是唯一转移灶。由于转移性疾病，24例患者中有23例改变了治疗方法;1例患者失访。结论:在任何既往或当前有甲状腺外恶性肿瘤病史的患者中，18F-PET/CT显示的甲状腺肿块或弥漫性甲状腺浸润应被认为是潜在的甲状腺内转移，除非证明不是这样。甲状腺内转移的知识可能会影响患者的治疗，特别是如果甲状腺或颈部是转移性疾病的唯一部位。

{"title":"18F-PET/CT imaging of metastasis to the thyroid gland: Imaging findings and effect on patient management.","authors":"Giovanni G Millare, Michael Kwon, Beth S Edeiken-Monroe, J Matthew Debnam","doi":"10.5430/jst.v7n2p7","DOIUrl":"https://doi.org/10.5430/jst.v7n2p7","url":null,"abstract":"Purpose: While metastasis to the thyroid from a primary cancer remote to the thyroid is uncommon, current imaging techniques have improved detection of these intrathyroid metastases. The purpose of this study was to evaluate the 18F-PET/CT appearance of intrathyroid metastases and assess the impact of detection on patient management.Methods: The 18F-PET/CT appearance of intrathyroid metastasis, including standardized uptake value (SUV), disease extent, and the effect on patient management following diagnosis were retrospectively reviewed. Inclusion criteria included 18F-PET/CT imaging and diagnosis of the intrathyroid metastasis matching the remote primary tumor.Results: Intrathyroid metastasis were detected in 24 patients. The intrathyroid metastases presented on 18F-PET/CT as focal nodular uptake (n = 21), multiple nodular uptake (n = 2), or diffuse uptake/infiltration of the thyroid gland (n = 1). The SUV ranged between 3.9 and 42 (median 12.5 ± 7.5); in 2 patients, the FDG-avidity was minimal. On 18F-PET/CT, distant metastases were present outside the neck (n = 18), or limited to the neck (n = 6). In 2 of these 6 patients, the thyroid was the only site of metastatic disease. Due to the metastatic disease, the therapy was changed in 23 of 24 patients; 1 patient was lost to follow-up.Conclusion: In any patient with a previous or current history of an extrathyroid malignancy, an 18FDG-avid thyroid mass or diffuse infiltration of the thyroid on 18F-PET/CT should be considered a potential intrathyoid metastasis until proven otherwise. Knowledge of an intrathyroid metastasis may impact patient management, especially if the thyroid or neck are the only sites of metastatic disease.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"7 2","pages":"7-13"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5430/jst.v7n2p7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36645889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

ARMS-PCR based diagnosis of APCB and KRAS genes in colorectal cancer patients in Iraqi Sulaimania province 基于ARMS-PCR的伊拉克苏莱曼尼亚省结直肠癌患者APCB和KRAS基因诊断

Journal of Solid Tumors

Pub Date : 2016-12-30 DOI: 10.5430/jst.v7n1p27

G. Salih, Shad Sudad

Amplification Refractory Mutation System (ARMS) assay is achieved for 30 blood samples of colorectal cancer (CRC) patients including 17 male and 13 female in order to determine the mutations in APCB gene and a proto-oncogene KRAS . ARMS-PCR analysis shows that all 30 samples are negative for I1307K variant ( APCB ) and seven common mutations in codons 12 and 13 ( APCB ). In addition two CRC patient samples are randomly chosen and purified for sequencing at Genome Center/KOYA University, then the sequence of the samples were BLAST on NCBI Website. The sequence alignment showed that both samples were wild for I1307K ( APCB ) and (G12S, G12C, G12A, G12D, G12V, G13D) ( KRAS ). We believe that these variants might absent in CRC patients of Iraqi Sulaimania province.

为了确定APCB基因和原癌基因KRAS的突变，对30例结直肠癌(CRC)患者(男性17例，女性13例)的血液样本进行了扩增难解突变系统(ARMS)检测。ARMS-PCR分析结果显示，30份样本均为I1307K变异(APCB)阴性，密码子12和13共有7个突变(APCB)阴性。另外，随机选取2例CRC患者样本，在KOYA大学基因组中心进行纯化测序，并在NCBI网站上BLAST测序。序列比对结果表明，I1307K (APCB)和(G12S, G12C, G12A, G12D, G12V, G13D) (KRAS)均为野生菌株。我们认为这些变异可能在伊拉克苏莱曼尼亚省的结直肠癌患者中不存在。

引用次数: 0

Effects of whole brain radiation on blood counts 全脑辐射对血液计数的影响

Journal of Solid Tumors

Pub Date : 2016-12-12 DOI: 10.5430/JST.V7N1P23

K. Foo, A. Patel, Gregory M. Richards, B. Goldsmith, A. Turtz, Piya V. Saraiya, R. Somer, N. Lerman, H. Goldman, G. Kubicek

Background: Whole brain radiation therapy is commonly used in the treatment of patients with CNS metastatic disease. Radiation to other areas of the body is associated with decrease in bone marrow proliferation. It is unclear what the effects ofWBRT have on blood counts. Methods: Retrospective chart review of patients with brain metastases treated with WBRT with recorded hematologic valuesbefore and after treatment. Univariate analysis was performed to identify statistical differences in outcome via paired t -testing. Results: Forty-nine patients were analyzed. Median age was 61 and 36 subjects were female. Analysis revealed significantly amedian decrease of 0.87 g/dL in hemoglobin values ( p .05). Conclusion: WBRT leads to a decrease in Hgb and platelets but does not appear to affect WBC counts. Physicians and patientsshould be aware of this side effect of WBRT.KeyWords: Whole brain radiotherapy, Anemia, Metastatic brain cancer

背景:全脑放射治疗是治疗中枢神经系统转移性疾病的常用方法。对身体其他部位的辐射与骨髓增殖的减少有关。目前还不清楚wbrt对血液计数有什么影响。方法:回顾性分析脑转移患者接受WBRT治疗前后的血液学指标。通过配对t检验进行单因素分析以确定结果的统计学差异。结果:对49例患者进行分析。中位年龄61岁，女性36例。分析显示血红蛋白值中位数显著降低0.87 g/dL (p . 0.05)。结论:WBRT导致Hgb和血小板减少，但似乎不影响白细胞计数。医生和患者都应该意识到WBRT的副作用。关键词:全脑放疗，贫血，转移性脑癌

引用次数: 2

Papillary mesothelioma of peritoneum involving fallopian tube: A challenging case 累及输卵管的腹膜乳头状间皮瘤:一个具有挑战性的病例

Journal of Solid Tumors

Pub Date : 2016-12-05 DOI: 10.5430/JST.V7N1P20

Asim Quershi, V. Gowri, I. Burney, M. A. Kalbani

Papillary mesothelioma is a well differentiated neoplasm arising from pelvic peritoneum of females in a wide age range. A typicalmorphological appearance is papillary structures with fibro vascular cores. We present a case of a 46-year-old female with a massin left peritoneal cavity involving the left fallopian tube which was excised and reported as a papillary mesothelioma.

乳头状间皮瘤是一种发生于骨盆腹膜的分化良好的肿瘤，可发生于各种年龄的女性。典型的形态表现为具有纤维血管核的乳头状结构。我们报告一位46岁女性病患，左侧腹膜腔肿大，累及左侧输卵管，经手术切除后报告为乳头状间皮瘤。

引用次数: 1

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Solid Tumors

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀